Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
Researchers at Johns Hopkins Kimmel Cancer Center found that tumor-associated epigenetic states evolve erratically during early stages of tumor development. This may help refine biomarkers for cancer risk stratification by screening specific genes in individuals of every age group.
Researchers create a computer program that predicts glioblastoma tumor growth with high accuracy, focusing on the role of L1CAM in accelerating cell spread. The model offers new opportunities for researchers to simulate various scenarios and test potential treatments.
Induced pluripotent stem cells have strong immunogenic properties that provoke a systemic, cancer-specific immune response. The study suggests iPS cells may one day be used as a patient-specific cancer vaccine, potentially preventing tumor development months or years later.
Researchers crack genetic code of malignant peripheral nerve sheath tumors and identify Lats1/2 as a gene that suppresses cancer, leading to rapid cell expansion. Disrupting overactive TAZ-YAP signaling reduces tumor growth in mice and human cells, offering new hope for MPNST treatment.
Researchers have discovered that naked mole rats are able to inhibit metabolic processes of senescent cells, making them less pathogenic. The rodents' cells also display increased resistance to DNA damage, which may be essential for their longevity and cancer resistance.
A team of researchers developed a fluorescent sensor, TiY, that selectively stains tumor initiating cells (TICs) in various cancer tissues. The sensor can distinguish TICs from non-TICs and inhibit sphere formation, leading to suppressed tumor growth in mice xenograft models.
A new study reveals how basal cell cancer responds to treatment and offers new ideas for controlling this disease. The researchers found that the relative location of a cell within a tumor can have a big effect on its sensitivity to drug treatment.
Researchers have created a stealth virus that effectively recognizes and infects tumor cells using adapter molecules. The virus is protected by a novel protein shield that prevents immune system elimination, opening up avenues for treating aggressive cancers.
Researchers discover that low levels of microRNA miR-125a-5p correlate with high levels of protein TIMP-1 in human lung cancer cells. Increasing miR-125a-5p levels reduces cancer spread and increases cell death. TIMP-1's role is also explored, revealing its dual function in promoting or inhibiting tumor growth.
A new video database has been created to track cellular migration, providing insights into normal processes and alterations involved in diseases like cancer. The database contains 52 videos analyzed from the Cell Tracking Challenge, offering a guide for researchers to select algorithmic solutions.
Researchers have developed a multifunctional vehicle using gold nanoparticles to transport and release the CRISPR-Cas9 system for targeted gene editing in tumors. The platform combines hyperthermal cancer therapy with genetic modification, offering a promising approach for tumor therapy.
A team of researchers has discovered that chromosomal instability can cause cancer cells to leak DNA, leading to a chronic inflammatory response that enables their spread. This finding opens up new possibilities for targeting metastasis in cancer treatment.
Scientists create nanoparticles that can penetrate extracellular matrix surrounding tumors, delivering chemotherapies specifically to cancer cells. The 'protocell' nanoparticle overcomes previous limitations by carving through the matrix and releasing drugs in acidic cell interiors, showing promise for treating solid tumors.
Rhabdomyosarcoma, the most prevalent soft tissue cancer in children, arises from immature progenitor cells that would normally develop into blood vessel cells, not muscle cells. The discovery opens a path for better treatments and may lead to new therapeutic drug targets.
A recent study published in the Journal of Experimental Medicine reveals that a common CLL treatment may be less effective in patients with a specific protein marker. Combining ibrutinib with drugs blocking this protein could prevent tumor cells from sheltering in lymphoid organs, leading to improved patient outcomes.
Researchers at the Medical University of South Carolina found that cancer cells use the unfolded protein response to alter their circadian rhythm, contributing to tumor growth. Misfolded proteins cause disruptions in this natural clockwork, allowing cancer cells to survive conditions that would kill normal cells.
Researchers developed a technique to pinpoint potential targets for cancer therapies that rely on the immune system. The technique identified two human antigens relevant to immunotherapies and found evidence of shared self-antigens between patients, offering a key to developing effective treatments.
IRB Barcelona researchers have discovered a new target for treating advanced prostate cancer, the TFIIF protein. Removing this protein's interaction with the androgen receptor could make treatment effective again in resistant tumors.
A new drug approach targets breast cancer's stem-like cells, slowing their spread before metastasis occurs. Researchers found co-expression of integrin αvβ3 and Slug identifies these cells in up to 20% of primary breast cancers.
Researchers found that low PUMA expression distinguishes stem-like cells in cancer patients who experienced tumor recurrence. Reducing PUMA restores metastasis in cultured cells, highlighting a possible Achilles heel in aggressive breast cancers.
A study published in Journal of Cell Biology identifies SUV420H2 as an epigenetic orchestrator of pancreatic cancer cells' aggressive behavior. Reducing SUV420H2 levels makes pancreatic cancer cells more vulnerable to existing therapies.
A team from Technical University of Munich has discovered a 'shut-off switch' in immune cells called PD-1 that prevents T cell Non-Hodgkin's lymphoma. The study found that PD-1 can turn off defective T cells at an early stage, preventing them from becoming tumor cells.
Researchers found that leftover cancer cell debris can stimulate tumor growth, but resolvins can block this response. The study suggests a new approach to enhance cancer therapy and prevent recurrence.
A new treatment aims to direct an immune response against a misshapen protein found exclusively on cancer cells, offering hope for children with deadly diffuse intrinsic pontine glioma. The protein target is a neoantigen that can be used to develop more selective and potent immunotherapies.
A new method using single-cell genomics can help identify potentially lethal prostate tumors before surgery, improving risk assessment and treatment decisions. The approach analyzes genomic patterns in biopsy cores, assigning a score based on clonality and genetic aberrations.
Researchers at Beth Israel Deaconess Medical Center have shown that chemotherapy-generated debris can stimulate tumor growth, but resolvins can suppress this effect. The findings offer a novel treatment approach to prevent cancer recurrence.
Researchers discovered that chemotherapy can stimulate tumor growth by inducing an inflammatory reaction in the body. Resolvins, a family of molecules, have been found to suppress this response, suggesting new ways to enhance cancer therapy effectiveness.
Research reveals that bone marrow-derived cells contribute to lung cancer progression by stimulating the production of specific neutrophils. These neutrophils exhibit increased expression of genes associated with tumor-promoting processes, leading to worse patient survival in a small study.
A new study at the University of Michigan identifies a pathway that links efferocytosis, the process of removing dead cells, to tumor growth in metastatic prostate cancer. The researchers found that a pro-inflammatory protein called CXCL5 accelerates tumor growth and sheds light on novel effective cancer therapies.
Researchers have identified a possible way to reengage a tumor suppressor protein, Growth Differentiation Factor 11, in triple-negative breast cancer cells. This could lead to the development of novel medications that can stop the aggressive form of cancer by intervening in its progression.
Scientists at NIST have discovered a way to make tiny colonies of cells grow in three-dimensional structures inside petri dishes, paving the way for more realistic biological environments for testing pharmaceuticals. The method could help bridge the gap between lab and living creature testing, speeding up drug development.
Researchers at Queen Mary University of London used CRISPR-dCas9 epigenetic editing to cause healthy breast cells to undergo 'hyperproliferation', a key early stage of tumour initiation. The findings could lead to the development of new biomarkers for earlier diagnosis and novel therapies.
Researchers have developed a novel approach to combat cancer using synthetic designer cells that mimic T-cells. These cells can detect and kill cancer cells while minimizing side effects, offering a promising new treatment option.
Researchers discovered a novel form of crosstalk among tumor cells and immune cells that inhibits the effectiveness of immunotherapeutic strategies. Combining CSF-1R inhibitors with selective CXCR2 inhibitors shows significant anti-tumor effects, suggesting new approaches to enhance therapeutic efficacy.
Researchers discovered that cells retain properties from their previous environment for several days, known as mechanical memory. This property can aid in tumor invasion and metastasis. The study's findings may lead to new insights into the mechanisms behind cancer spread.
Researchers discovered that different types of brain tumors and brain cancer cells share common energy production processes, enabling them to adapt and grow in the brain. This study aims to identify new targets for treatment and potentially develop drugs specifically designed to target these survival mechanisms.
Researchers argue that identifying molecular subtypes of different cells within tumors can improve breast cancer treatment. They advocate for more accurate diagnostic tests to capture irregularities between tumor cells, which are often treated as a whole.
For-Robin's monoclonal antibody JAA-F11 successfully targets and kills human breast cancer cells in human tumors grafted into mice, effectively treating triple-negative breast cancer. The company is now focusing on fundraising and preparing for human clinical trials to bring its product from the bench to the bedside.
Researchers at the Francis Crick Institute have identified a novel protein that exclusively targets Wnt signalling in tumour cells, reducing growth of colon cancer cells without harming healthy cells.
Researchers have identified melanocytes as the origin of cutaneous melanoma, a deadly form of skin cancer. These cells are reprogrammed to become invasive and migratory cancer cells, leading to tumor formation.
Researchers at the Wyss Institute for Biologically Inspired Engineering have developed a human lung-on-a-chip technology that models the growth and metastatic behaviors of non-small cell lung cancer. The study found that tumor cells grow rampantly in the alveolar microenvironment but remain quiescent in the airway chip, and that cyclic...
International experts have identified a new protein called ZATT that can directly clean DNA breaks without degradation, allowing for more efficient repair and potentially increasing chemotherapy sensitivity. This breakthrough has the potential to improve treatment outcomes and enable personalized therapies.
A new computer program called SCENIC enables researchers to quickly and accurately identify different cell types in the human body. The method helps understand how cell fate is regulated and could lead to the discovery of master regulators and potential drug targets.
Researchers have developed a new software tool that reveals molecular connections between breast cancer tumor cells and immune system cells in the bloodstream. The study found that these connections vary depending on the type of breast cancer, potentially leading to new treatment and monitoring strategies.
The UA Cancer Center's research may lead to ways to target metastatic tumors by altering the depth of quiescence in cancer cells. This could make it easier for chemotherapy drugs to target and kill these cells.
Researchers at Cologne University Hospital have discovered a novel inhibitor that specifically targets NMC tumours, a rare and lethal form of cancer. The study's findings provide valuable insights into the molecular mechanism responsible for the effectiveness of the inhibitor, paving the way for new and improved therapies.
Researchers at Children's Hospital Los Angeles identified a molecular pathway in an immune cell called a tumor-associated macrophage that supports neuroblastoma, a pediatric cancer. Targeting the STAT3 pathway with a clinically available drug may be a promising approach to improve outcomes for children with high-risk neuroblastoma.
Researchers at Weizmann Institute of Science find that oxygen-starved killer T cells are more effective at destroying cancerous tumors and outperform regular T cells in a mouse model. The study suggests an easy improvement to existing immunotherapy protocols.
Scientists discovered how cancer-fighting Natural Killer cells power up and how cholesterol-like molecules cut them off. Activated NK cells use a unique energy production system that can be disrupted by oxysterols, which may explain poor performance in patients with high cholesterol levels.
Researchers at The Wistar Institute have discovered a novel metastasis suppressor pathway orchestrated by the mitochondrial protein SNPH. This pathway promotes tumor cell proliferation in local growth but inhibits invasion and metastasis. By studying SNPH, scientists may uncover new therapeutic approaches to target metastatic cells.
A new blood test can predict how early-stage lung cancer patients will fare, identifying clusters of aggressive tumor cells that indicate shorter survival times. The test uses circulating tumor cells in the bloodstream to monitor cancer progression and resistance to treatments.
Researchers suggest that combining drugs blocking PAF-R protein may increase radiotherapy's killing of tumor cells by one third and reduce tumor repopulation. Analysis with human oral cancer cells and murine cervical cancer cells showed promising results, supporting a new therapeutic strategy.
Researchers at UT Southwestern Medical Center report that tumors stressed by cancer immunotherapy release mitochondrial DNA into nearby immune cells, triggering a host alert system. This discovery highlights the critical role of cGAS as an innate immune sensor for DNA and its importance in bridging the body's two immune systems.
A compound has been identified that enhances tumor-targeting viruses' ability to selectively kill liver cancer cells while sparing healthy ones. The oncolytic virus M1 was boosted by combining it with Eeyarestatin I, increasing its potency 3,600-fold against cancer cells in culture and animal models.
A new blood test developed by TUM researchers can predict drug resistance in patients with advanced prostate cancer, analyzing AR-V7 RNA molecules for early detection. The test has shown high sensitivity and accuracy, identifying approximately one-fifth of patients with large amounts of resistant tumor cells.
Researchers at Lund University identified a specific marker (CD44) that interacts with protein HIF-2a, allowing cancer stem cells in glioblastoma to adapt to oxygen deprivation. This interaction enables the growth of more aggressive tumor cells, which are resistant to treatment and contribute to recurrence.
Researchers have designed a complex sugar molecule that binds to galectin-1, enabling the immune system to recognize and attack tumor cells. This breakthrough could lead to the development of new drugs and rapid tests for early cancer detection.
A research team at Lund University has discovered that gene expression in normal tissue varies depending on the location within the kidney. This variation affects the accuracy of comparisons between tumour cells and healthy tissue, leading to a better understanding of kidney cancer subtypes.
Researchers at the University of Portsmouth have identified two molecules, CD15s and CD62E, that play a key role in brain tumor cells binding to blood vessels. By blocking these molecules, it may be possible to prevent brain tumors from developing in patients with non-small cell lung cancer.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a novel synthetic lethality screen to discover molecules that target genetically modified yeast lacking NF1. The team identified one lead candidate called Y100, which disrupts tumor cell growth and induces oxidative stress causing death of NF1-deficient cancer cells.